Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
POZN > SEC Filings for POZN > Form 8-K on 28-Nov-2012All Recent SEC Filings

Show all filings for POZEN INC /NC

Form 8-K for POZEN INC /NC


Other Events

Item 8.01. Other Events.

On November 21, 2012, POZEN Inc., a Delaware corporation ("POZEN" or "the Company"), AstraZeneca AB ("AstraZeneca"), and AstraZeneca's United States affiliate, AstraZeneca Pharmaceuticals, LP, received notice from Dr. Reddy's Laboratories, Inc. ("DRL") pursuant to 21 U.S.C. 355(j)(2)(A)(vii)(IV) (the "Paragraph IV Notice Letter"), that DRL had filed an Abbreviated New Drug Application ("ANDA") with the United States Food and Drug Administration ("FDA") seeking regulatory approval to market a generic version of VIMOVOŽ (naproxen and esomeparazole magnesium) delayed release tablets before the expiration of U.S. Patent Nos. 5,714,504; 6,926,907; 5,900,424; 7,745,466; 7,411,070; and 6,369,085. The patents are among those listed with respect to VIMOVO in the FDA's Approved Drug Products with Therapeutic Equivalents Evaluation publication (commonly referred to as the "Orange Book") and expire at various times between 2016 and 2023. DRL's Paragraph IV Notice Letter asserts that its generic product will not infringe the listed patents or that the listed patents are invalid or unenforceable.

This is the second ANDA that DRL has filed with the FDA seeking regulatory approval to market a generic version of VIMOVO. On March 14, 2011, the Company and AstraZeneca received a Paragraph IV Notice Letter from DRL informing us that it had filed an ANDA with the FDA seeking regulatory approval to market a generic version of VIMOVO and, accordingly, the Company and AstraZeneca filed suit against Dr. Reddy's on April 21, 2011in the United States District Court for the District of New Jersey. The case has been consolidated with the case against Lupin, Ltd. and Anchen Pharmaceuticals, Inc., both of which have filed ANDAs with the FDA to market generic versions of VIMOVO prior to the expiration of the Company's and AstraZeneca's patents. The case is currently in the discovery phase and initial claim construction positions have been exchanged.

The Company and AstraZeneca are evaluating new DRL's Paragraph IV Notice Letter.

  Add POZN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for POZN - All Recent SEC Filings
Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.